Fabio Pucci is a Senior Director of Venture Investments at Leaps by Bayer since October 2021 and serves on the board of directors for several biotech companies, including Dewpoint Therapeutics, Lyterian Therapeutics, Mozart Therapeutics, Capstan Therapeutics, Indapta Therapeutics, Immunitas Therapeutics, and Boundless Bio. Additionally, Fabio Pucci acts as a board observer for Kojin Therapeutics. Engagement in academia includes a role as an adjunct professor for the "Business of Biotechnology" master's course at Northeastern University. Fabio Pucci holds an MBA from London Business School and a PhD in Cell/Cellular and Molecular Biology from The University of Edinburgh.